November 1, 2023 - Regulatory SynAct Pharma announces evaluation of the 4-week RESOLVE P2a clinical trial in moderate to severely active rheumatoid arthritis patients with an incomplete response to methotrexate
October 12, 2023 - Regulatory SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm
October 11, 2023 - Regulatory SynAct Pharma AB carries out a directed issue of shares and warrants raising initial gross proceeds of SEK 60.5 million
September 12, 2023 - Regulatory SynAct Pharma announces additional data from the EXPAND P2b clinical trial and identifies population with responsiveness to resomelagon
September 4, 2023 - Regulatory SynAct Pharma announces top line data from the 12-week EXPAND P2b clinical trial in severely active newly diagnosed rheumatoid arthritis patients
May 25, 2023 - Regulatory Bulletin from the annual general meeting in SynAct Pharma AB on May 25, 2023
April 24, 2023 - Regulatory SynAct Pharma completes patient recruitment for Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis
April 3, 2023 - Regulatory The Nomination Committee of SynAct Pharma proposes Uli Hacksell as new Chairman and Thomas von Koch as new Board member
February 1, 2023 - Regulatory Patrik Renblad is leaving SynAct Pharma and the search for a new CFO has been initiated
